Online Therapy for Insomnia Linked to Improved Mental Health

This article originally appeared here.
Share this content:
Online Therapy for Insomnia Linked to Improved Mental Health
Online Therapy for Insomnia Linked to Improved Mental Health

MONDAY, Sept. 11, 2017 (HealthDay News) -- For university students with insomnia, digital cognitive behavioral therapy (CBT) is associated with reductions in insomnia, paranoia, and hallucinations, according to a study published online Sept. 6 in The Lancet Psychiatry.

Daniel Freeman, Ph.D., from the University of Oxford in the United Kingdom, and colleagues conducted a single-blind trial at 26 universities. A total of 3,755 students with insomnia were randomized to receive digital CBT for insomnia (1,891 participants) or usual care (1,864 participants), and were assessed online at weeks zero, three, 10 (end of treatment), and 22.

The researchers found that the sleep intervention correlated with reductions in insomnia, paranoia, and hallucinations at 10 weeks, compared with usual practice (adjusted difference, 4.78, −2.22, and −1.58, respectively). In paranoia and hallucinations, insomnia was a mediator of change. There were no reports of adverse events.

"To our knowledge, this is the largest randomized controlled trial of a psychological intervention for a mental health problem. It provides strong evidence that insomnia is a causal factor in the occurrence of psychotic experiences and other mental health problems," the authors write. "Whether the results generalize beyond a student population requires testing. The treatment of disrupted sleep might require a higher priority in mental health provision."

Several authors disclosed financial ties to pharmaceutical, publishing, and health care companies, including Sleepio and Big Health Ltd., which provided the sleep treatment program to trial participants at no cost.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »